A detailed history of City Holding CO transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, City Holding CO holds 20 shares of CRSP stock, worth $925. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20
Previous 75 73.33%
Holding current value
$925
Previous $4,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 08, 2024

SELL
$44.62 - $62.75 $2,454 - $3,451
-55 Reduced 73.33%
20 $0
Q2 2024

Jul 12, 2024

SELL
$51.17 - $68.18 $511 - $681
-10 Reduced 11.76%
75 $4,000
Q1 2024

Apr 11, 2024

SELL
$60.67 - $89.12 $1,759 - $2,584
-29 Reduced 25.44%
85 $5,000
Q4 2023

Jan 10, 2024

SELL
$38.62 - $72.18 $2,317 - $4,330
-60 Reduced 34.48%
114 $7,000
Q3 2023

Oct 13, 2023

SELL
$45.39 - $59.0 $71,262 - $92,630
-1,570 Reduced 90.02%
174 $7,000
Q2 2023

Jul 13, 2023

SELL
$43.47 - $67.77 $21,735 - $33,885
-500 Reduced 22.28%
1,744 $97,000
Q1 2023

Apr 17, 2023

SELL
$41.0 - $56.12 $27,470 - $37,600
-670 Reduced 22.99%
2,244 $101,000
Q4 2022

Jan 27, 2023

SELL
$39.19 - $65.67 $18,223 - $30,536
-465 Reduced 13.76%
2,914 $0
Q3 2022

Oct 12, 2022

SELL
$61.1 - $83.78 $21,996 - $30,160
-360 Reduced 9.63%
3,379 $221,000
Q2 2022

Jul 08, 2022

SELL
$43.23 - $73.83 $152,818 - $260,989
-3,535 Reduced 48.6%
3,739 $227,000
Q1 2022

Apr 15, 2022

SELL
$53.19 - $79.24 $10,106 - $15,055
-190 Reduced 2.55%
7,274 $457,000
Q4 2021

Mar 11, 2022

BUY
$70.09 - $111.29 $26,423 - $41,956
377 Added 5.32%
7,464 $458,000
Q3 2021

Oct 15, 2021

BUY
$110.2 - $156.64 $316,604 - $450,026
2,873 Added 68.18%
7,087 $793,000
Q2 2021

Jul 15, 2021

BUY
$100.84 - $161.89 $117,680 - $188,925
1,167 Added 38.3%
4,214 $682,000
Q1 2021

Apr 15, 2021

BUY
$110.72 - $210.04 $337,363 - $639,991
3,047 New
3,047 $371,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.61B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track City Holding CO Portfolio

Follow City Holding CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of City Holding CO, based on Form 13F filings with the SEC.

News

Stay updated on City Holding CO with notifications on news.